In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Applied Genetic Technologies (NASDAQ: AGTC). The company’s shares closed yesterday at $4.95, close to its 52-week low of $4.45.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -17.9% and a 31.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ImmunoCellular Therapeutics, and Iovance Biotherapeutics Inc.
Applied Genetic Technologies has an analyst consensus of Moderate Buy.
Based on Applied Genetic Technologies’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $8.39 million and GAAP net loss of $821K. In comparison, last year the company earned revenue of $12.11 million and had a net profit of $2.73 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Applied Genetic Technologies Corp. is a clinical-stage biotechnology company, which engages in the development of gene therapy products designed to transform the lives of patients with severe diseases in ophthalmology. Its product candidates are designed to treat X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa.